Susquehanna Fundamental Investments LLC Makes New $503,000 Investment in Omada Health, Inc. $OMDA

Susquehanna Fundamental Investments LLC bought a new stake in Omada Health, Inc. (NASDAQ:OMDA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 22,900 shares of the company’s stock, valued at approximately $503,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in shares of Omada Health in the 2nd quarter worth approximately $32,000. Bellevue Group AG raised its holdings in Omada Health by 0.7% during the third quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock worth $5,567,000 after purchasing an additional 1,791 shares in the last quarter. Quarry LP bought a new stake in Omada Health during the fourth quarter worth approximately $29,000. Barclays PLC lifted its position in Omada Health by 14.6% in the fourth quarter. Barclays PLC now owns 14,850 shares of the company’s stock worth $234,000 after purchasing an additional 1,888 shares during the period. Finally, Versant Capital Management Inc boosted its stake in Omada Health by 319.3% during the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after purchasing an additional 2,283 shares in the last quarter.

Insider Buying and Selling at Omada Health

In other Omada Health news, President Wei-Li Shao sold 8,866 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $25.02, for a total value of $221,827.32. Following the completion of the sale, the president directly owned 307,372 shares of the company’s stock, valued at $7,690,447.44. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Steven L. Cook sold 1,108 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $25.00, for a total transaction of $27,700.00. Following the transaction, the chief financial officer owned 187,209 shares in the company, valued at $4,680,225. This represents a 0.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 255,834 shares of company stock valued at $5,398,196. 6.38% of the stock is currently owned by insiders.

Omada Health Stock Up 2.1%

Shares of NASDAQ:OMDA opened at $23.31 on Thursday. The firm has a fifty day moving average of $22.59 and a two-hundred day moving average of $17.46. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92. The firm has a market capitalization of $1.43 billion, a P/E ratio of 466.20 and a beta of 1.86.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.10. Omada Health had a return on equity of 2.60% and a net margin of 1.39%.The business had revenue of $87.83 million during the quarter, compared to analysts’ expectations of $80.93 million. Equities research analysts expect that Omada Health, Inc. will post 0.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on OMDA shares. Morgan Stanley reaffirmed an “overweight” rating and set a $30.00 target price on shares of Omada Health in a report on Monday, June 22nd. Wells Fargo & Company raised their price objective on shares of Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Weiss Ratings raised shares of Omada Health from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen upgraded shares of Omada Health from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $26.50.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.